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Enhanced autophagy has been observed in hypoxic regions of solid tumors. Here we address the hypothesis that
autophagy is required for survival of hypoxic cells. We evaluated sensitivity to hypoxia of three human tumor cell
lines (MCF7, PC3, and LNCaP) and their autophagy-deficient variants with shRNA knockdown of the genes ATG7
and BECLIN1. Hypoxia-induced cell death was more rapid for autophagy-deficient cells and was increased in the
presence of the proton pump inhibitor pantoprazole that inhibits autophagy. Autophagy-deficient cells had a lower
rate of oxygen consumption than wild-type cells. In xenografts derived from the three cell lines, autophagy (as
determined by increased LC3 and reduced p62/SQSTM1) colocalized with hypoxic regions (identified by EF5).
Xenografts derived from autophagy-deficient cells grew more slowly than wild-type tumors. Both LC3 expression
and hypoxia were decreased in xenografts generated from single-knockdown cells and absent in double-
knockdown tumors. Our results are consistent with the hypothesis that autophagy facilitates the survival of
hypoxic cells, although reduced oxygen consumption of autophagy-deficient cells may contribute to lack of
hypoxia in tumors derived from them. Because hypoxia is associated with resistance to anticancer therapy,
inhibition of autophagy has potential to enhance the effectiveness of cancer treatment.
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Tumor hypoxia is associated with a decrease in the effectiveness of
radiation therapy and chemotherapy, and with a poor prognosis [1].
Autophagy is a cellular mechanism used to digest old or damaged
cellular constituents into component residues, which may be recycled
to generate essential macromolecules. All cells undergo autophagy,
but it is upregulated in stressed cells such as those with nutrient or
growth factor depletion; such conditions are common in the
microenvironment of solid tumors, and autophagy colocalizes with
regions of hypoxia [2]. In cancer development, autophagy has been
shown to have a dual role [3]: in some studies, autophagy promotes
tumorigenesis, but in others, autophagy is a tumor-suppressive
mechanism.
Autophagy involves the formation of autophagosomes, which have
a double membrane enclosing cytoplasmic cellular components; this
then fuses with a lysosome to produce a mature autolysosome in
which cellular proteins are degraded by cathepsins [4]. A series of
autophagy-related proteins (known as ATGs) is responsible for theinduction and regulation of autophagy [5], and some of them can be
used as markers of autophagy that can be quantified in Western Blots
or by immunohistochemistry (IHC) applied to tumor sections. Beclin
1, the mouse homolog of yeast ATG6, encodes a Bcl-2–interacting
candidate tumor suppressor and antiviral protein [6]. Molecular
alterations in Beclin 1 are common in human cancers, and beclin 1
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hematopoietic malignancies [7]. Beclin1 and its binding partner class
III phosphoinositide 3-kinase are required for vesicle nucleation and
the formation of autophagosomes in the early phase of autophagy [8].
During autophagosome maturation, microtubule-associated protein
light-chain 3 (LC3-I) is cleaved and then conjugated with
phosphatidylethanolamine into LC3-II, a process mediated by the
proteins ATG7 and ATG3 that mediate later stages of autophagy [9].
Lipidated LC3-II is bound to the membrane of the autophagosome
until fusion with the lysosome is complete. It is then broken down
and recycled. Thus, LC3-II acts as a biochemical marker for
induction of autophagy, although agents that inhibit later stages of
autophagy, including the acidification of lysosomes or their fusion
with autophagosomes, will prevent breakdown of LC3-II and lead to
increased levels of this protein [10]. An additional autophagy marker,
p62/SQSTM1 (p62), is recruited with LC3-II to autophagosomes
and degraded within the mature autolysosome [11]. Thus,
observation of increased p62 is indicative of a build-up of the protein
due to inhibition of lysosomal fusion to the autophagosome, i.e., to
inhibition of autophagy.
Hypoxia occurs in tissue when the oxygen demand exceeds oxygen
supply. Tumor hypoxia often correlates with poor outcome, and
although hypoxic cells in tumors eventually die, there is evidence that
they are resistant to apoptosis [12]. The mechanisms of hypox-
ia-induced cell death remain unclear because apoptosis, necrosis, and
autophagy have all been reported in response to hypoxia [13].
Hypoxia has been shown to induce autophagy in different cellular
settings [14], and autophagy might act as a survival mechanism for
hypoxic cells through recycling of cellular constituents. Pharmaco-
logical inhibition of autophagy has been shown to enhance apoptosis
and cell death under hypoxic conditions [15]. Autophagy levels were
found to correlate with the expression of hypoxia-inducible factor 1α
and have been associated with early invasion in colon cancer [16].
Recent reports also showed that hypoxia is able to upregulate
autophagy, leading to cell survival and resistance to anticancer
therapies [17].
Agents which inhibit endosomal acidification, including (hydro-
xy)chloroquine and proton pump inhibitors such as pantoprazole,
lansoprazole, and omeprazole, can suppress the later stages of
autophagy [18,19], thereby inhibiting breakdown of LC3-II. Some
studies, including those from our laboratory, have shown that proton
pump inhibitors can sensitize cancer cells and solid tumors to
different chemotherapeutic agents [20,21]. We have also shown that
treatment of cancer cells in vitro and of solid tumors in mice with a
wide variety of anticancer agents induces autophagy, suggesting that it
is a common survival mechanism for drug-treated cells and therefore
an important cause of drug resistance. It is not known how hypoxia
and autophagy interact to modulate cancer cell response to
hypoxia-induced or chemotherapy drug-induced cell death. The
aim of the present study was to understand the implications of
hypoxia and autophagy in tumors and to address the hypothesis that
autophagy is a survival mechanism for hypoxic cells.
Methods
Cell Lines
Human prostate cancer PC3 and LNCaP cells and human breast
carcinoma MCF7 cells were purchased from the American Type
Culture Collection (Manassas, VA) in 2011. PC3 and LNCaP cellswere grown in Ham’s F-12K medium (Life Technologies Inc,
Burlington, ON, Canada); MCF7 cells were grown in α-minimum
essential medium supplemented with 10% FBS (Hyclone, Logan,
UT). All cells were cultured in a humidified atmosphere of 95% air/
5% CO2 at 37°C, and experiments were performed on fourth and
fifth passages generated from frozen stock. Routine tests to exclude
mycoplasma in all cell lines were conducted at least once per year.
Short tandem repeat analysis was conducted to ensure that cells (PC3,
LNCaP, and MCF-7) were of human origin in May 2013.
Generation of Autophagy-Deficient Cells
Lentiviral shRNA (ATG7 and BECLIN1) constructs were
purchased from Open Biosystems (RMM4534_019584 and
RMM4534_028835) (Ottawa, ON, Canada). ATG7 and BECLIN1
shRNAs were transfected into PC3, LNCaP, or MCF7 cells either
alone or together with packaging plasmids following the manufac-
turer's protocol (Invitrogen ViraPower Lentiviral Expression Systems
kit, Carlsbad, CA). Cells were passaged and plated in a six-well plate
and allowed to adhere for 24 hours before infection. The silencing
efficacy of the various shRNAs was assessed by Western blot analysis
of ATG7 and BECLIN1 proteins using polyclonal antibodies
(Sigma-Aldrich, Oakville, ON, Canada).
Cell Survival under Hypoxic Conditions
PC3, LNCaP, and MCF7 cells (wild type and autophagy deficient)
were plated at a density of 1 × 105 cells in 10-cm3 plates and cultured
for 24 hours in RPMI or alpha-MEM supplemented with 10% FBS.
Cells were then exposed to aerobic conditions (20% oxygen) or
hypoxia (0.2% oxygen) for 0, 12, 24, 36, and 48 hours. For exposure
to hypoxia or control (aerobic) conditions, cells were incubated in a
humidified HypOxygen H35 workstation; the atmosphere in the
chamber consisted of 5% H2, 5% CO2, the desired % O2, and
residual N2. Samples were removed as a function of time, centrifuged,
washed, and plated in serial dilution in plastic tissue culture dishes.
Colonies generated 8 to 14 days later were stained with methylene
blue and counted.
The short-term MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium CellTiter
96 AQueous one Solution Cell proliferation Assay; Promega
Corperation, Madison, WI) was used to evaluate the effects of
pantoprazole on viability of PC3, LNCaP, and MCF7 cells exposed
under aerobic or hypoxic (0.2% oxygen) conditions. Pantoprazole
(PANTO IV) was purchase from Sanofi Inc. (Laval, Quebec, Canada)
as a lyophilized powder and dissolved in 0.9% saline. Cells were
seeded at 2000 to 4000 cells per well, depending on the optimal
conditions for each cell line, into 96-well plates and incubated
overnight. Cells were treated with or without pantoprazole (100 μM)
under aerobic conditions or 0.2% oxygen for 24 hours. After 24-hour
treatment, medium was removed and the cells were washed twice
with PBS. Cell viability was determined according to the manufac-
turer’s protocol.
Evaluation of Autophagy by Western Blot Analysis
Wild-type and autophagy-deficient PC3, LNCaP, and MCF7 cells
treated with or without pantoprazole under aerobic or hypoxic
conditions for 24 hours were lysed in RIPA buffer and centrifuged at
13,000g at 4°C for 30 minutes to collect the supernatant. Protein
concentration was determined using a Bio-Rad Protein Assay
(Bio-Rad Laboratories, Hercules, CA). A total of 20 μg of protein
Figure 1. (A and B) Western blots to confirm knockdown of ATG7 and BECLIN1 in each cell line (numbers indicate relative ATG7 and
BENCLIN1 protein level compared with wild-type (WT) cell line).The surviving fraction of PC3 (C), LNCaP (D), and MCF7 (E) WT and
autophagy-deficient cells as a function of time under hypoxic conditions as determined by a colony-forming assay (zero time indicates
control aerobic condition). Data represent mean ± SEM (n = 3). For each cell line, differences between curves for WT and each
autophagy-deficient cell line are significant (P b .001).
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electrophoresis and transferred to a polyvinylidene fluoride mem-
brane (Millipore, Etobicoke, ON, Canada). The membrane was
washed in Tris-buffered saline and Tween 20 and blocked with 5%
skim-milk + 2% FBS in Tris-buffered saline and Tween 20.
Membranes were incubated with primary antibodies overnight at
4°C followed by appropriate horseradish peroxidase–conjugated
secondary antibodies. Protein concentration in the supernatant was
determined using a Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA) to quantify LC3-II and p62. Protein levels were
quantified using Image Pro software (Version premier 9).
Xenograft Experiments
Animal experiments were carried out using Animal Use Protocol
(AUP1232.15, 09/05/14) approved by Princess Margaret Cancer
Centre, University Health Network Animal Care Committee under
the guidelines of the Canadian Council on Animal Care.
To generate xenografts, 4- to 6-week-old male athymic nude (Nu/
Nu) mice (Jackson Laboratory, Bar Harbor, Maine) were injected
subcutaneously in both flanks with 2 × 106 wild-type or
autophagy-deficient PC3 or LNCaP cells. Four- to 6-week-old
female athymic nude (Nu/Nu) mice (Harlan Sprague-Dawley,
Madison, WI) with implanted 17β-estradiol tablets (60-day release;
Innovative Research of America, Sarasota, FL) were injectedsubcutaneously with 5 × 106 wild-type or autophagy-deficient
MCF7 cells per side.
Mice bearing xenografts were divided into groups of six mice to
measure tumor growth rate. Two perpendicular diameters of tumors
growing in the flanks of mice were measured with a caliper every 2 to
3 days. Measurements were taken until tumors reached a maximum
diameter of 1.5 cm or began to ulcerate, when mice were killed
humanely. Tumor volume was estimated using the formula 0.5(ab2),
where a is the longest diameter and b is the shortest diameter. To
verify that xenografts generated from autophagy-deficient cells
retained their phenotype, RNA was extracted from mature xenografts
using TRI Reagent with DNase I digestion of contaminating DNA.
cDNA was synthesized using a reverse transcriptase kit. Primer-probe
sets for quantitative polymerase chain reaction (qPCR) and PCR
master mix were supplied by Sigma (Oakville, ON, Canada). Samples
were quantified against serial dilutions of standards of plasmids
containing the target sequences to provide copy number.
At the end of the growth rate assay, tumors were excised for IHC to
detect hypoxia and other biomarkers in sections of xenografts (mean
cross-section area for wild-type tumors was 1.2-1.3 cm2, ATG7 and
BECLIN1 knockdown tumors were 0.5-0.6 cm2, double-knock-
down tumors were 0.2-0.3 cm2). Wild-type tumors might have more
hypoxia because of their larger size. To avoid bias, we therefore also
measured the hypoxic fraction in smaller wild-type tumors with mean
Figure 2. Effect of pantoprazole on viability of WT and autophagy-deficient PC3 (A), LNCaP (B), and MCF7 (C) cells following 24-hour
exposure to aerobic or hypoxic conditions as evaluated by the MTS assay. Data represent mean ± SEM (n= 3). *Significant difference (P
b .01) between autophagy-deficient and WT cells under areobic conditions. **Significant difference (P b .005) between
autophagy-deficient and WT cells under hypoxic conditions. The difference in viability of hypoxic cells in the presence or absence of
pantoprazole is significant (P b .05). (D and E) Effect of pantoprazole on expression of LC3-II and p62 by Western blot assay. (LC3-II, p62,
and β-actin intensities were normalized to control.)
350 Autophagy as a Survival Mechanism for Hypoxic Cells Tan et al. Neoplasia Vol. 18, No. 6, 2016cross-sectional area of 0.4-0.6 cm2, similar to that of tumors grown
from the single-knockdown cells
The hypoxia marker EF5 was injected intraperitoneally approximately
2 hours before killing themice (0.2ml of a 10-mMstock permouse). EF5
was provided by the National Cancer Institute as a powder and then
dissolved in distilled water supplemented with 2.4% ethanol and 5%
dextrose to make a 10-mM stock solution that was stored at room
temperature. To detect functional blood vessels, the perfusion marker
DiOC7 (1 mg/kg) was injected intravenously 1 minute before killing the
mice. DiOC7 was purchased from AnaSpec (San Jose, CA), and a stock
solution (2.5 mg/ml) was made by dissolving in dimethyl sulfoxide; this
stock was diluted 1:10 in phosphate-buffered saline and 10% Solutol HS
15 (Sigma-Aldrich, Oakville, ON, Canada). Tumors were excised,
embedded in OCT compound, frozen in liquid nitrogen, and stored at −
70°C. Whole cryostat sections (10 μm thick) were analyzed, and artifacts
and regions of necrosis were excluded. Tumor sections were first imaged
for DiOC7 using a FITC filter set. Sections were then stained for hypoxic
regions using a Cy5-conjugated mouse anti-EF5 antibody (1:50)
purchased from Dr. Cameron Koch, University of Pennsylvania,
Philadelphia, PA. Hypoxic regions were quantified by calculating
the area of pixels with anti-EF5 fluorescence and dividing this region
by the area of the entire tumor section (artifacts and regions of necrosis
were omitted).The same tumor sections were also stained with appropriate
antibodies to the biomarkers LC3A and p62 (to quantify autophagy)
and Ki-67 (to quantify cell proliferation). Ki-67 was identified with a
primary rabbit antihuman Ki-67 antibody (Novus Biologicals,
Oakville, ON, Canada). LC3A was recognized with a rabbit
anti-human LC3A primary antibody, and p62 was recognized with
a rabbit anti-human p62 primary antibody (ABGENT, San Diego,
CA). Application of all primary antibodies was followed by
Cy3-conjugated goat anti-rabbit IgG secondary antibody, and the
sections were imaged with a Cy3 filter set (530-560 nm excitation/
573-746 nm emission) using an Olympus fluorescent upright
microscope. Image analysis and quantification of biomarker distri-
bution in relation to blood vessels and regions of hypoxia were
performed as described previously [22].
Measurement of Basal Oxygen Consumption Rate
Oxygen consumption rates were measured using Seahorse
Biosciences extracellular flux analyzer (XFe 96, North Billerica,
MA). Cells were seeded at 2.3 × 104 cells per well (0.32 cm2) in XFe
96 plates in 250 μl of Dulbecco’s modified Eagle’s medium (10%
FBS, 1% Pen-Strep) and incubated for 24 hours at 37°C and 8.5%
CO2 before XF assay. Oxygen consumption was measured under
basal conditions, in the presence of the mitochondrial inhibitor
Figure 3. Growth curves for PC3 (A), LNCaP (B), and MCF7 (C) WT and autophagy-deficient xenografts (10-12 tumors in 6 mice per group,
experiments were repeated twice). (D) qPCR was used to confirm knockdown status of tumors generated from autophagy-deficient cells
of the indicated genotypes (WT represents wild type; DK represents double knockdown). Data represent mean ± SEM, n = 3.
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uncoupler p-trifluoromethoxy carbonyl cyanide phenyl hydrazone
(FCCP, 1 μM) to assess maximal oxidative capacity.
Statistical Analysis
One-way analysis of variance followed by Tukey’s post hoc test
determined statistical differences between treatment groups. For
two-group comparisons, the Student’s t test was used. P b .05 was
used to indicate statistical significance. All experiments were repeated
at least three times. Drug and biomarker distributions are represented
as mean values ± SEM.Results
Autophagy-Deficient Cells More Sensitive to Hypoxia
The silencing efficacy of the various shRNA was assessed by
weste2rn blot analysis of ATG7 and BECLIN1 proteins (Figure 1, A
and B). Double-knockdown cells were also generated, but they did
not grow in cell culture, although they did generate xenografts (see
below). The survival of wild-type and autophagy-deficient PC-3,
LNCaP, and MCF7 cells under hypoxic conditions (relative to
aerobic conditions) is shown in Figure 1, C–E. All three cell lines had
a decrease in cell survival under hypoxic conditions after 24 to 48
hours of exposure, and this hypoxia-induced cell death was morerapid for autophagy-deficient cells, with the BECLIN1 knockdown
cells being most sensitive (P b .001 for each comparison).
To obtain further evidence about the role of autophagy in hypoxic
cells, we used the short-term MTS assay to evaluate viability of
wild-type and autophagy-deficient cells exposed for 24 hours to
aerobic or hypoxic conditions in the presence or absence of
pantoprazole, an inhibitor of the late stages of autophagy. The
knockdown cells had lower viability than the wild-type cells (P b .01
for ATG7 or BECLIN1 knockdown compared with wild type) under
aerobic conditions but relatively greater loss of viability under hypoxic
conditions (Figure 2, A and C). Pantoprazole (100 μM) was found to
reduce viability in the hypoxic cell population (P b .05) as well as
under aerobic conditions (P b .05, Figure 2, A and C), suggesting
that autophagy is a cytoprotective mechanism.
The influence of pantoprazole on expression of the autophagy
markers LC3-II and p62 in PC3 wild-type cells under aerobic and
hypoxic conditions is shown in Figure 2D. Hypoxia induced
~two-fold accumulation of LC3II and degradation of p62 consistent
with induction of autophagy. Pantoprazole, which inhibits autophagy
and leads to inhibition of breakdown of LC3-II and p62 degradation
[23], increased LC3-II and p62 under both hypoxic and aerobic
conditions. Figure 2E shows parallel results for PC3 knockdown cells
deficient in ATG7 and BECLIN1. As expected, the Western blots
indicate decreased levels of LC3-II and increased p62 under all
Figure 4. (A and B) LC3 and p62 in relation to hypoxic regions in WT, ATG7, BECLIN1 knockdown, and double-knockdown (DK) PC3
xenografts. (C) Ki67 in relation to functional blood vessels (indicated by DiOC7) in WT and knockdown PC3 xenografts. (D)
Photomicrographs of Ki67 (yellow) in relation to functional blood vessels (recognized by DioC7 red) and hypoxia (recognized by EF5 blue)
inWT and knockdown xenografts. Means and SEs are for 10 tumors per group; bar, SE. Differences betweenWT and autophagy-deficient
xenografts are significant (P b .0001).
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blots to evaluate LC3-II in LNCaP and MCF7 cells showed similar
results (data not shown).
Xenografts Generated from Wild-Type and Autophagy-
Deficient Cells
Xenografts generated from the autophagy-deficient PC3, LNCaP,
and MCF7 cells grew more slowly than those derived from wild-type
cells (Figure 3, A and C). The double-knockdown xenografts had the
slowest growth (P b .005 compared with wild type), whereas there
was no significant difference between the growth curves for xenografts
derived from ATG7 and BECLIN1 knockdown cells for any of the
three human tumor xenografts. When animals were killed at the end
of the growth experiment and their tumors were isolated and freshly
prepared, qPCR was used to confirm their genotype (Figure 3D).
We used IHC to quantify the markers of autophagy LC3 and p62
in relation to the closest functional blood vessel (recognized by
DioC7, data not shown) and closest region of hypoxia (recognized by
EF5) in PC3 wild-type and autophagy-deficient xenografts (Figure 4,
A and B). LC3 expression was maximal in hypoxic and poorly
nourished regions in wild-type tumors, markedly decreased in those
generated from ATG7 and BECLIN1 knockdowns, and absent indouble-knockdown tumors. As expected, p62 showed least expression
in wild-type xenografts and maximal expression in the double-knock-
down tumors. We also used IHC to evaluate the spatial distribution
of the proliferation marker Ki67. Cell proliferation decreased with
increasing distance from functional blood vessels in wild-type tumors,
but consistent with their slower growth rate, expression of Ki67 was
reduced in xenografts generated from single- and double-knockdown
PC3 cells (Figure 4, C and D).
The proportion of hypoxia was compared in sections of xenografts
of the three cell lines excised at the end of the growth rate experiment
where median volumes of the excised single- and double-knockdown
xenografts were ~40% and ~15%, respectively, relative to that of the
wild-type xenografts (Figure 5A). The proportion of hypoxia in
tumors derived from knockdown cells with that in smaller wild-type
tumors of similar volume is shown in Figure 5B. Hypoxic regions
(recognized by EF5) were reduced in the autophagy-deficient
xenografts, with minimal hypoxia in the double-knockdowns of all
three cell lines.
Oxygen Consumption byWild-Type and Autophagy-Deficient Cells
Measurements of oxygen consumption rates of wild-type and
autophagy-deficient PC3, LNCaP, and MCF7 cells are shown in
Figure 5. Proportion of hypoxia in WT and knockdown xenografts as a proportion of viable tissue in tumor sections. (A) Tumors were
excised at the end of the growth rate experiment (mean cross-section areas: for WT tumors 1.2-1.3 cm2, ATG7 and BECLIN1 knockdown
tumors 0.5-0.6 cm2, double-knockdown tumors 0.2-0.3 cm2).(B) WT xenografts were excised at smaller size (mean cross sectional:
0.4-0.6 cm2). Means and SEs are for 10 tumors per group; bar, SE. Differences between WT and autophagy-deficient xenografts are
significant (P b .001).
Figure 6. Oxygen consumption rates in WT and knockdown cells (A) PC3, (B) LNCaP, and (C) MCF7. Shown is the mean fold difference ±
SEM in oxygen consumption under basal conditions and following the addition of oligomycin (0.5 μM) or the pharmacological uncoupler
FCCP (1 μM) (WT basal oxygen consumption rates = 1) obtained from experiments each performed in triplicate. Differences betweenWT
and single-knockdown cells are significant (P b .05). Differences between WT and double-knockdown cells are significant (P b .001).
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presence of the ATPase inhibitor oligomycin to block respiration, and
in the presence of the uncoupler FCCP to induce maximum
respiration. Autophagy-deficient cells had significantly lower rates of
oxygen consumption under both basal and modified conditions.
Discussion
Results in the present paper show that if autophagy is inhibited by
RNA interference of the key regulators ATG7 or BECLIN1 or by
treatment with pantoprazole, different types of human tumor cells die
more quickly when exposed to hypoxic conditions in tissue culture
(Figures 1 and 2). Autophagy-deficient cells also consumed less
oxygen than wild-type cancer cells (Figure 6) consistent with previous
reports that silencing of ATG7, ATG5, and BECLIN1 promotes the
accumulation of dysfunctional mitochondria and low oxygen
consumption in prostate, lung, and pancreatic cancers [24,25].
Xenografts derived from autophagy-deficient cells grew more slowly
than those derived from wild-type cells and had lower rates of cell
proliferation, consistent with their lower rate of oxidative metabolism
(Figures 3 and 4C). The autophagy marker LC3 was increased (and
p62 decreased) in hypoxic regions of wild-type PC3 tumors,
expression of LC3 was markedly reduced (and p62 increased) in
xenografts derived from single-knockdown cells, and LC3 was not
detected (and p62 was maximal) in those derived from double-knock-
down cells (Figure 4, A and B). Moreover, the proportion of hypoxia
in tumor sections was reduced in xenografts derived from
single-knockdown cells, and there was no detectable hypoxia in
xenografts derived from double-knockdown cells (Figure 5). These
data support the hypothesis that autophagy is a survival mechanism
for hypoxic cells, although the reduced oxygen consumption of
autophagy-deficient cells may contribute to reduced hypoxia in
tumors generated from them.
The development of hypoxic regions within tumors promotes
resistance against radiotherapy and chemotherapy and is associated
with poor outcome of human tumors, even when treated by surgery.
Likewise, autophagy, a process that allows recycling of constituent
molecules in cells, has been associated with resistance to therapy and
poor outcome. Although basal autophagy occurs in most cells,
autophagy is activated by various stresses such as nutrient depletion
(including hypoxia) or treatment with chemotherapy [26]. Markers of
autophagy are increased in many types of cancer, and most evidence
suggests that they function to promote survival of tumor cells. It has
been shown that autophagy is induced in hypoxic regions of tumors
where it promotes survival [13]. Further studies have confirmed the
molecular connections between hypoxia and the induction of
autophagy. Hypoxia-inducible factor 1α is a positive regulator of
autophagy; stimulates tumor metabolism, angiogenesis, and metas-
tasis; and is associated with resistance to therapy in hypoxic tumors
[27]. Induction of BNIP3 and BNIP3L in hypoxic cells disrupts the
BECLIN1-BCL-2 complex, thereby releasing BECLIN1 to induce
autophagy, and BNIP3-induced autophagy is an adaptive survival
response during hypoxia [14].
Several cancer therapies induce autophagy, and the autophagic
response to some treatments has been shown to be cytoprotective [28].
Our previous work and that of others indicate that autophagy is
upregulated by treatment with a variety of anticancer drugs and is
probably a general mechanism leading to drug resistance [29]. Inhibiting
autophagy therefore has the potential to restore sensitivity of tumor cells,
especially nutrient-deprived and hypoxic cells, to cancer treatment.Strengths of our study are that it includes both in vitro and in vivo
studies of three different human tumor cell lines that add to the
current understanding of how autophagy contributes to the survival
of hypoxic cells and thus to limitations of cancer treatment. It also
uses both genetic and pharmacologic inhibition of autophagy to
demonstrate increased sensitivity of cancer cells. Potential weaknesses
of our study include failure to generate double-knockdown cells that
can grow in tissue culture. Also, we assessed the efficacy of shRNA
knockdown of autophagy by testing three commercially available
shRNAs and picking the most deficient knockdown cell lines. We did
not clone these knockdown cell line,s but we demonstrated that the
phenotype remained stable following their growth as xenografts.
Conclusion
In summary, our data support the hypothesis that autophagy is a
survival mechanism for hypoxic cells both in tissue culture and in
experimental tumors. Our findings have substantial implications
because both hypoxia and autophagy are associated with poor
outcome for human cancers and are associated with resistance to
treatment. Inhibiting autophagy in tumors might be exploited to
increase the efficacy of anticancer treatment.
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